The dual-functionality of A1, acting as both a CXCR4 inhibitor and a cytotoxic agent, suggests its potential as a promising candidate for enhancing CRC treatment strategies (Khorramdelazad et al., 2023). Here, CXCR4 is linked to colorectal carcinoma.